Trials / Completed
CompletedNCT04382586
Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary Distress
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study was to evaluate if the addition of zanubrutinib to supportive care increases the respiratory failure-free survival rate at Day 28 in participants hospitalized for Corona Virus Disease 2019 (COVID-19) and pulmonary distress not receiving mechanical ventilation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanubrutinib | 320 mg (4 x 80 mg) capsules administered orally once daily |
| DRUG | Supportive Care | Supportive care treatment was selected and administered as deemed appropriate by the study investigator |
| DRUG | Placebo | Placebo to match zanubrutinib |
Timeline
- Start date
- 2020-07-06
- Primary completion
- 2021-02-01
- Completion
- 2021-02-01
- First posted
- 2020-05-11
- Last updated
- 2024-10-26
- Results posted
- 2022-03-02
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04382586. Inclusion in this directory is not an endorsement.